Search

Your search keyword '"Licitra, L"' showing total 1,115 results
Start Over Author "Licitra, L"
1,115 results on '"Licitra, L"'

1. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors

Author

Lewis, K.D., Peris, K., Sekulic, A., Stratigos, A.J., Dunn, L., Eroglu, Z., Chang, A.L.S., Migden, M.R., Yoo, S.-Y., Mohan, K., Coates, E., Okoye, E., Bowler, T., Baurain, J.-F., Bechter, O., Hauschild, A., Butler, M.O., Hernandez-Aya, L., Licitra, L., Neves, R.I., Ruiz, E.S., Seebach, F., Lowy, I., Goncalves, P., and Fury, M.G.

Published
2024
Full Text
View/download PDF

3. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

Author

Schlumberger, M, Elisei, R, Müller, S, Schöffski, P, Brose, M, Shah, M, Licitra, L, Krajewska, J, Kreissl, MC, Niederle, B, Cohen, EEW, Wirth, L, Ali, H, Clary, DO, Yaron, Y, Mangeshkar, M, Ball, D, Nelkin, B, and Sherman, S

Subjects
Cancer, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Anilides, Carcinoma, Medullary, Diagnostic Imaging, Double-Blind Method, Female, Follow-Up Studies, Humans, International Agencies, Male, Prognosis, Pyridines, Survival Rate, Thyroid Neoplasms, cabozantinib, medullary thyroid cancer, progression-free survival, overall survival, RET M918T, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundPrimary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement in progression-free survival with cabozantinib versus placebo in patients with progressive medullary thyroid cancer (MTC). Final analysis of overall survival (OS), a key secondary endpoint, was carried out after long-term follow-up.Patients and methodsEXAM compared cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomized (2:1) to cabozantinib (140 mg/day) or placebo. Final OS and updated safety data are reported.ResultsMinimum follow-up was 42 months. Kaplan-Meier analysis showed a 5.5-month increase in median OS with cabozantinib versus placebo (26.6 versus 21.1 months) although the difference did not reach statistical significance [stratified hazard ratio (HR), 0.85; 95% confidence interval (CI), 0.64-1.12; P = 0.24]. In an exploratory assessment of OS, progression-free survival, and objective response rate, cabozantinib appeared to have a larger treatment effect in patients with RET M918T mutation-positive tumors compared with patients not harboring this mutation. For patients with RET M918T-positive disease, median OS was 44.3 months for cabozantinib versus 18.9 months for placebo [HR, 0.60; 95% CI, 0.38-0.94; P = 0.03 (not adjusted for multiple subgroup analyses)], with corresponding values of 20.2 versus 21.5 months (HR, 1.12; 95% CI, 0.70-1.82; P = 0.63) in the RET M918T-negative subgroup. Median treatment duration was 10.8 months with cabozantinib and 3.4 months with placebo. The safety profile for cabozantinib remained consistent with that of the primary analysis.ConclusionThe secondary end point was not met in this final OS analysis from the trial of cabozantinib in patients with metastatic, radiographically progressive MTC. A statistically nonsignificant increase in OS was observed for cabozantinib compared with placebo. Exploratory analyses suggest that patients with RET M918T-positive tumors may experience a greater treatment benefit with cabozantinib.Trial registration numberNCT00704730.

Published
2017

4. Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

Author

Keam, B., Machiels, J.-P., Kim, H.R., Licitra, L., Golusinski, W., Gregoire, V., Lee, Y.G., Belka, C., Guo, Y., Rajappa, S.J., Tahara, M., Azrif, M., Ang, M.K., Yang, M.-H., Wang, C.-H., Ng, Q.S., Wan Zamaniah, W.I., Kiyota, N., Babu, S., Yang, K., Curigliano, G., Peters, S., Kim, T.W., Yoshino, T., and Pentheroudakis, G.

Published
2021
Full Text
View/download PDF

5. Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Author

Machiels, J.P., primary, TAO, Y., additional, Burtness, B., additional, Tahara, M., additional, Rischin, D., additional, Alves, G.V., additional, Lima, I.P. Figueiredo, additional, Hughes, B.G.M., additional, Pointreau, Y., additional, Aksoy, S., additional, Laban, S., additional, Greil, R., additional, Burian, M., additional, Hetnal, M., additional, Licitra, L., additional, Black, C.M., additional, Norquist, J., additional, Gumuscu, B., additional, Bidadi, B., additional, and Siu, L.L., additional

Published
2024
Full Text
View/download PDF

6. Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study

Author

Harrington, K., primary, Kim, H.R., additional, Salas, S., additional, Oliva, M., additional, Metcalf, R., additional, Bernsdorf, M., additional, Kim, J.W., additional, Cohen, E., additional, Siu, L.L., additional, Rischin, D., additional, Licitra, L., additional, Vermorken, J., additional, Le, Q.T., additional, Tahara, M., additional, Machiels, J.P., additional, O'Hara, K., additional, Pathiraja, K., additional, Gumuscu, B., additional, Bidadi, B., additional, and Burtness, B., additional

Published
2024
Full Text
View/download PDF

7. Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study

Author

Licitra, L., primary, Tahara, M., additional, Harrington, K., additional, de Mendoza, M. Olivera Hurtado, additional, Guo, Y., additional, Aksoy, S., additional, Fang, M., additional, Żurawski, B., additional, Csőszi, T., additional, Klochikhin, M., additional, de Oliveira, T.B., additional, Takahashi, S., additional, Yang, M.H., additional, Swiecicki, P.L., additional, O'Hara, K., additional, Shen, J., additional, Wang, A., additional, Gumuscu, B., additional, Benjamin, K., additional, and Haddad, R.I., additional

Published
2024
Full Text
View/download PDF

10. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Author

Adelstein, D.J., Agarwal, J., Alfonsi, M., Argiris, A., Aupérin, A., Bacigalupo, A., Bar-Ad, V., Bartelink, H., Beadle, B., Belkacemi, Y., Bensadoun, R.J., Bernier, J., Blanchard, P., Bourhis, J., Bratland, Å., Brizel, D., Budach, V., Budach, W., Burtness, B., Calais, G., Campbell, B., Caudell, J., Chabaud, S., Chamorey, E., Chaukar, D., Cheugoua-Zanetsie, M., Cho, K.H., Choussy, O., Cruz Hernandez, J.J., Denham, J.W., Dobrowsky, W., Dominello, M.M, Driessen, C.M.L., Fallai, C., Forastiere, A.A., Fortpied, C., Fountzilas, G., Garaud, P., Garden, A.S., Gery, B., Ghadjar, P., Ghi, M.G., Ghosh Laskar, S., Graff-Cailleaud, P., Grau, C., Gregoire, V., Hackshaw, A., Haddad, E, Haffty, B.G., Hansen, A., Hay, J.H., Hayoz, S., Horiot, J.C., Hitt, R., Jeremic, B., Johansen, J., Jones, C., Julieron, M., Kristensen, C.A., Kumar, S., Lacas, B., Langendijk, J.A., Lapeyre, M., Lartigau, E., Licitra, L., Le, Q.T., Lee, J.W., Lee, P., Lewin, F., Li, Y., Lopes, A., Lotayef, M., Maciejewski, B., Mazeron, J.J., Mehta, S., Michalski, W., Moon, J., Moon, S.H., Moyal, E., Nankivell, M., Nilsson, P., Olmi, P., Orecchia, R., O'Sullivan, B., Overgaard, J., Parmar, M.K.B., Petit, C., Pignon, J.P., Pointreau, Y., Posner, M.R., Poulsen, M.G., Quon, H., Racadot, S., Rosenthal, D.I., Rovea, P., Ruo Redda, M.G., Sanguineti, G., Shenouda, G., Simes, J., Sharma, A., Simon, C., Sire, C., Skladowski, K., Spencer, S., Staar, S., Strojan, P., Stromberger, C., Suwinski, R., Szutkowski, Z., Takácsi-Nagy, Z., Tao, Y.G., Temam, S., Thomson, D., Tobias, J.S., Torres-Saavedra, P., Torri, V., Tripcony, L., Trotti, A., Tseroni, V., van Herpen, C., van Tinteren, H., Vermorken, J., Viegas, C.M.P., Vokes, E.E., Waldron, J., Wernecke, K.D, Widder, J., Wolf, G.T., Wong, S.J., Wu, J.S., Yamazaki, H., Zaktonik, B., Zackrisson, B., Zhong, L.P., Petit, Claire, Lacas, Benjamin, Pignon, Jean-Pierre, Le, Quynh Thu, Grégoire, Vincent, Grau, Cai, Hackshaw, Allan, Zackrisson, Björn, Parmar, Mahesh K B, Lee, Ju-Whei, Ghi, Maria Grazia, Sanguineti, Giuseppe, Temam, Stéphane, Cheugoua-Zanetsie, Maurice, O'Sullivan, Brian, Posner, Marshall R, Vokes, Everett E, Cruz Hernandez, Juan J, Szutkowski, Zbigniew, Lartigau, Eric, Budach, Volker, Suwiński, Rafal, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Jeremic, Branislav, Simes, John, Zhong, Lai-Ping, Overgaard, Jens, Fortpied, Catherine, Torres-Saavedra, Pedro, Bourhis, Jean, Aupérin, Anne, and Blanchard, Pierre

Published
2021
Full Text
View/download PDF

14. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Author

Ferris, R.L., Haddad, R., Even, C., Tahara, M., Dvorkin, M., Ciuleanu, T.E., Clement, P.M., Mesia, R., Kutukova, S., Zholudeva, L., Daste, A., Caballero-Daroqui, J., Keam, B., Vynnychenko, I., Lafond, C., Shetty, J., Mann, H., Fan, J., Wildsmith, S., Morsli, N., Fayette, J., and Licitra, L.

Published
2020
Full Text
View/download PDF

17. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer

Author

Cavalieri, S., Perrone, F., Miceli, R., Ascierto, P.A., Locati, L.D., Bergamini, C., Granata, R., Alfieri, S., Resteghini, C., Galbiati, D., Busico, A., Paielli, N., Patuzzo, R., Maurichi, A., Gallino, G., Ruggeri, R., Mariani, L., Palla, M., Licitra, L., and Bossi, P.

Published
2018
Full Text
View/download PDF

19. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Author

Bossi, P., Miceli, R., Locati, L.D., Ferrari, D., Vecchio, S., Moretti, G., Denaro, N., Caponigro, F., Airoldi, M., Moro, C., Vaccher, E., Sponghini, A., Caldara, A., Rinaldi, G., Ferrau, F., Nolè, F., Lo Vullo, S., Tettamanzi, F., Hollander, L., and Licitra, L.

Published
2017
Full Text
View/download PDF

20. MO-0717 Seasonality of radiotherapy efficacy for head & neck cancer patients: MACH-NC/MARCH meta-analyses

Author

Blanchard, P., primary, Lacas, B., additional, Bourhis, J., additional, Limkin, E., additional, Parmar, M., additional, Licitra, L., additional, Le, Q., additional, Fortpied, C., additional, Langendijk, J., additional, Vermorken, J., additional, Bernier, J., additional, Trotti, A., additional, Overgaard, J., additional, Harris, J., additional, Pignon, J., additional, and Aupérin, A., additional

Published
2023
Full Text
View/download PDF

23. The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers.

Author

Trama, A., Licitra, L., Cavalieri, S., Bonfarnuzzo, S., Baili, P., Ciarfella, A., Parente, P., Almadori, G., Ansarin, M., Bacigalupo, A., Baumeister, P., Baujat, B., Bossi, P., Cavalera, E., Cercato, M.C., Dieleman, F., Fakhry, N., Ferraresi, V., Gaino, F., Galizia, D., Halamkova, J., Halme, E., Hardillo, J., Hofauer, B., Kinloch, E., Livi, L., Locati, L.D., Mattheis, S., Mercante, G., Mirabile, A., Molteni, G., Orlandi, E., Persio, R., Sciallero, S., Smeele, L., Tagliabue, M., Valentini, V., Herpen, C.M.L. van, Westphalen, C.Benedikt, Botta, L., Trama, A., Licitra, L., Cavalieri, S., Bonfarnuzzo, S., Baili, P., Ciarfella, A., Parente, P., Almadori, G., Ansarin, M., Bacigalupo, A., Baumeister, P., Baujat, B., Bossi, P., Cavalera, E., Cercato, M.C., Dieleman, F., Fakhry, N., Ferraresi, V., Gaino, F., Galizia, D., Halamkova, J., Halme, E., Hardillo, J., Hofauer, B., Kinloch, E., Livi, L., Locati, L.D., Mattheis, S., Mercante, G., Mirabile, A., Molteni, G., Orlandi, E., Persio, R., Sciallero, S., Smeele, L., Tagliabue, M., Valentini, V., Herpen, C.M.L. van, Westphalen, C.Benedikt, and Botta, L.

Abstract

Item does not contain fulltext, INTRODUCTION: Care for head and neck cancers is complex in particular for the rare ones. Knowledge is limited and histological heterogeneity adds complexity to the rarity. There is a wide consensus that to support clinical research on rare cancer, clinical registries should be developed within networks specializing in rare cancers. In the EU, a unique opportunity is provided by the European Reference Networks (ERN). The ERN EURACAN is dedicated to rare adults solid cancers, here we present the protocol of the EURACAN registry on rare head and neck cancers (ClinicalTrials.gov Identifier: NCT05483374). STUDY DESIGN: Registry-based cohort study including only people with rare head and neck cancers. OBJECTIVES: to help describe the natural history of rare head and neck cancers;to evaluate factors that influence prognosis;to assess treatment effectiveness;to measure indicators of quality of care. METHODS: Settings and participants It is an hospital based registry established in hospitals with expertise in head and neck cancers. Only adult patients with epithelial tumours of nasopharynx; nasal cavity and paranasal sinuses; salivary gland cancer in large and small salivary glands; and middle ear will be included in the registry. This registry won't select a sample of patients. Each patient in the facility who meets the above mentioned inclusion criteria will be followed prospectively and longitudinally with follow-up at cancer progression and / or cancer relapse or patient death. It is a secondary use of data which will be collected from the clinical records. The data collected for the registry will not entail further examinations or admissions to the facility and/or additional appointments to those normally provided for the patient follow-up. Variables Data will be collected on patient characteristics (eg. patient demographics, lifestyle, medical history, health status); exposure data (eg. disease, procedures, treatments of interest) and outcomes (e.g. survival, progressi

Published
2023

24. Current management and future challenges in salivary glands cancer

Author

Locati, L, Ferrarotto, R, Licitra, L, Benazzo, M, Preda, L, Farina, D, Gatta, G, Lombardi, D, Nicolai, P, Vander Poorten, V, Chua, M, Vischioni, B, Sanguineti, G, Morbini, P, Fonseca, I, Sozzi, D, Merlotti, A, Orlandi, E, Locati, L, Ferrarotto, R, Licitra, L, Benazzo, M, Preda, L, Farina, D, Gatta, G, Lombardi, D, Nicolai, P, Vander Poorten, V, Chua, M, Vischioni, B, Sanguineti, G, Morbini, P, Fonseca, I, Sozzi, D, Merlotti, A, and Orlandi, E

Abstract

Salivary gland cancers (SGCs) are rare, accounting for less than 5% of all malignancies of the head and neck region, and are morphologically heterogeneous. The diagnosis is mainly based on histology, with the complementary aid of molecular profiling, which is helpful in recognizing some poorly differentiated, borderline, or atypical lesions. Instrumental imaging defines the diagnosis, representing a remarkable tool in the treatment plan. Ultrasound and magnetic resonance are the most common procedures used to describe the primary tumour. The treatment of SGCs is multimodal and consists of surgery, radiotherapy, and systemic therapy; each treatment plan is, however, featured on the patient and disease’s characteristics. On 24 June 2022, in the meeting “Current management and future challenges in salivary gland cancers” many experts in this field discussed the state of the art of SGCs research, the future challenges and developments. After the meeting, the same pool of experts maintained close contact to keep these data further updated in the conference proceedings presented here. This review collects the insights and suggestions that emerged from the discussion during and after the meeting per se.

Published
2023

28. Genomic Adjusted Radiation Dose (GARD) Predicts Overall Survival and Outperforms AJCC 8th Edition in Prognostication of HPV-Positive Oropharyngeal Squamous Cell Carcinoma

Author

Ho, E., primary, De Cecco, L., additional, Cavalieri, S., additional, Serafini, M.S., additional, Pistore, F., additional, Lenoci, D., additional, Hoebers, F.J.P., additional, Brakenhoff, R.H., additional, Leemans, C.R., additional, Scheckenbach, K., additional, Poli, T., additional, Campbell, S.R., additional, Yang, K., additional, Eschrich, S.A., additional, Koyfman, S.A., additional, Licitra, L., additional, Torres-Roca, J.F., additional, and Scott, J.G., additional

Published
2022
Full Text
View/download PDF

37. Corrigendum: “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” (European Journal of Cancer (2021) 157 (250–258), (S0959804921005360), (10.1016/j.ejca.2021.08.018))

Author

Baggi, A., Quaglino, P., Rubatto, M., Depenni, R., Guida, M., Ascierto, P. A., Trojaniello, C., Queirolo, P., Saponara, M., Peris, Ketty, Spagnolo, F., Bianchi, L., De Galitiis, F., Potenza, M. C., Proietti, I., Marconcini, R., Botticelli, A., Barbieri, Pietro Vittorio, Licitra, L., Alfieri, S., Ficorella, C., Cortellini, A., Fargnoli, Maria Concetta, Troiani, T., Tondulli, L., Zamparini, M., Bossi, P., Peris K. (ORCID:0000-0002-5237-0463), Barbieri V., Fargnoli M. C., Baggi, A., Quaglino, P., Rubatto, M., Depenni, R., Guida, M., Ascierto, P. A., Trojaniello, C., Queirolo, P., Saponara, M., Peris, Ketty, Spagnolo, F., Bianchi, L., De Galitiis, F., Potenza, M. C., Proietti, I., Marconcini, R., Botticelli, A., Barbieri, Pietro Vittorio, Licitra, L., Alfieri, S., Ficorella, C., Cortellini, A., Fargnoli, Maria Concetta, Troiani, T., Tondulli, L., Zamparini, M., Bossi, P., Peris K. (ORCID:0000-0002-5237-0463), Barbieri V., and Fargnoli M. C.

Abstract

The authors regret that some Author information was incorrectly given in the published article. Author Manuel Zamparini was missed in the Author list, and the listed affiliation for Paola Queirolo was incorrect. The full and correct details for the Authors are: Paola Queirolo Division of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy Manuel Zamparini University of Brescia, Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, ASST-Spedali Civili, Brescia, Lombardia, ItalyThe Authors also note that values in the first column of Table 4 were mistakenly reversed for ‘Antibiotic intake (within 1 month before therapy)’ and ‘Haemoglobin’. The correct table in full is given here.

Published
2022

38. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Author

Cohen, E. E. W., Licitra, L. F., Burtness, B., Fayette, J., Gauler, T., Clement, P. M., Grau, J. J., del Campo, J. M., Mailliez, A., Haddad, R. I., Vermorken, J. B., Tahara, M., Guigay, J., Geoffrois, L., Merlano, M. C., Dupuis, N., Krämer, N., Cong, X. J., Gibson, N., Solca, F., Ehrnrooth, E., and Machiels, J.-P. H.

Published
2017
Full Text
View/download PDF

41. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study

Author

Psyrri, A., Fortpied, C., Koutsodontis, G., Avgeris, M., Kroupis, C., Goutas, N., Menis, J., Herman, L., Giurgea, L., Remenár, É., Degardin, M., Pateras, I. S., Langendijk, J. A., van Herpen, C. M. L., Awada, A., Germà-Lluch, J. R., Kienzer, H. R., Licitra, L., and Vermorken, J. B.

Published
2017
Full Text
View/download PDF

46. Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy

Author

Harrington, K., primary, Cohen, E., additional, Siu, L., additional, Rischin, D., additional, Licitra, L., additional, Vermorken, J., additional, Le, Q.T., additional, Tahara, M., additional, Machiels, J.P., additional, Hawk, N., additional, Ge, J., additional, Bidadi, B., additional, Swaby, R., additional, and Burtness, B., additional

Published
2022
Full Text
View/download PDF

48. A Clinically Translatable, Extensively Validated Immune-based Classification of Human Papillomavirus-Associated Head and Neck Cancer With Implications for Treatment Deintensification and Immunotherapy

Author

Zeng, P., primary, Cecchini, M., additional, Barrett, J., additional, Shammas-Toma, M., additional, De Cecco, L., additional, Serafini, M., additional, Cavalieri, S., additional, Licitra, L., additional, Hoebers, F., additional, Brakenhoff, R., additional, Leemans, C., additional, Scheckenbach, K., additional, Poli, T., additional, Wang, X., additional, Liu, X., additional, Laxague, F., additional, Prisman, E., additional, Poh, C., additional, Bose, P., additional, Dort, J., additional, Shaikh, M., additional, Ryan, S., additional, Dawson, A., additional, Khan, M., additional, Howlett, C., additional, Stecho, W., additional, Plantinga, P., additional, da Silva, S., additional, Hier, M., additional, Khan, H., additional, MacNeil, D., additional, Mendez, A., additional, Yoo, J., additional, Fung, K., additional, Lang, P., additional, Winquist, E., additional, Palma, D., additional, Ziai, H., additional, Li, S., additional, Boutros, P., additional, Mymryk, J., additional, and Nichols, A., additional

Published
2022
Full Text
View/download PDF

50. Corrigendum to 'Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma' [Eur J Canc 157 (2021) 250-258]

Author

Baggi, A, Quaglino, P, Rubatto, M, Depenni, R, Guida, M, Ascierto, Pa, Trojaniello, C, Queirolo, P, Saponara, M, Peris, K, Spagnolo, F, Bianchi, L, De Galitiis, F, Potenza, Mc, Proietti, I, Marconcini, R, Botticelli, A, Barbieri, V, Licitra, L, Alfieri, S, Ficorella, C, Cortellini, A, Fargnoli, Mc, Troiani, T, Tondulli, L, Zamparini, M, and Bossi, P

Subjects
Cancer Research, Settore MED/35, Oncology
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results